Allogene Therapeutics (ALLO) Revenue & Revenue Breakdown
Allogene Therapeutics Revenue Highlights
Latest Revenue (Y)
$95.00K
Latest Revenue (Q)
$22.00K
Allogene Therapeutics Revenue by Period
Allogene Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $95.00K | -60.91% |
| 2022-12-31 | $243.00K | -99.37% |
| 2021-12-31 | $38.49M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Allogene Therapeutics generated $95.00K in revenue during NA 2023, up -60.91% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Allogene Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $22.00K | 4.76% |
| 2023-12-31 | $21.00K | -51.16% |
| 2023-09-30 | $43.00K | -2.27% |
| 2023-06-30 | $44.00K | -15.38% |
| 2023-03-31 | $52.00K | 10.64% |
| 2022-12-31 | $47.00K | -4.08% |
| 2022-09-30 | $49.00K | -43.02% |
| 2022-06-30 | $86.00K | 40.98% |
| 2022-03-31 | $61.00K | 19.61% |
| 2021-12-31 | $51.00K | 4.08% |
| 2021-09-30 | $49.00K | 11.36% |
| 2021-06-30 | $44.00K | -99.89% |
| 2021-03-31 | $38.34M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | - |
Allogene Therapeutics generated $22.00K in revenue during Q1 2024, up 4.76% compared to the previous quarter, and up 46.81% compared to the same period a year ago.
Allogene Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BEAM | Beam Therapeutics | $377.71M | $11.77M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| SGMO | Sangamo Therapeutics | $176.23M | $356.00K |
| HRTX | Heron Therapeutics | $127.04M | $46.54M |
| GTHX | G1 Therapeutics | $82.51M | $16.55M |
| NTLA | Intellia Therapeutics | $36.27M | $6.96M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| VECT | VectivBio | $27.34M | $676.00K |
| RLAY | Relay Therapeutics | $25.55M | - |
| ITOS | iTeos Therapeutics | $12.60M | - |
| VERV | Verve Therapeutics | $11.76M | $5.70M |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| ALLO | Allogene Therapeutics | $95.00K | $22.00K |
| EDIT | Editas Medicine | - | - |
| PRME | Prime Medicine | - | - |
| ANNX | Annexon | - | - |
| SANA | Sana Bio | - | - |
ALLO Revenue FAQ
What is Allogene Therapeutics’s yearly revenue?
Allogene Therapeutics's yearly revenue for 2023 was $95K, representing a decrease of -60.91% compared to 2022. The company's yearly revenue for 2022 was $243K, representing a decrease of -99.37% compared to 2021. ALLO's yearly revenue for 2021 was $38.49M, representing an increase of 100.00% compared to 2020.
What is Allogene Therapeutics’s quarterly revenue?
Allogene Therapeutics's quarterly revenue for Q1 2024 was $22K, a 4.76% increase from the previous quarter (Q4 2023), and a -57.69% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $21K, a -51.16% decrease from the previous quarter (Q3 2023), and a -55.32% decrease year-over-year (Q4 2022). ALLO's quarterly revenue for Q3 2023 was $43K, a -2.27% decrease from the previous quarter (Q2 2023), and a -12.24% decrease year-over-year (Q3 2022).
What is Allogene Therapeutics’s revenue growth rate?
Allogene Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -99.75%, and for the last 5 years (2019-2023) was 0%.